# ADM Step 6 — AI-Output Decision Evidence

Status: **PERSONAL DECISION CONFIRMED**. This file preserves only evidence actually present in the project and does not treat the documented explanation as a verified verbatim Codex response.

Personal confirmation date: **October 17, 2026**.

## Available factual evidence

| Source | What it documents | What it does not document |
|---|---|---|
| `adm_model_documentation.md`, “AI assistance” | Codex assisted with the integrated Python model, supplied Lab 10 inputs, validations, FCFF/scenarios, output, and documentation. | A verbatim Codex recommendation and the student’s accept/correct/qualify/reject action. |
| `Lab10-notes.md`, “AI Disclosure” | ChatGPT/Codex helped organize financial data, develop/troubleshoot the pro-forma model, check calculations, format tables, and clarify writing; the student says they reviewed the work and take responsibility. | A dated, specific AI proposal and a documented individual decision about it. |
| `adm_model_documentation.md`, “Remaining judgment calls” | The record identifies unresolved analyst choices, including tax, terminal growth, dividend, facility policy, leases, affiliates, and market inputs. | Which of those choices was first proposed by AI and what the student decided in response. |

## Required personal completion

This table records the Step 5 revenue-growth explanation as an AI-assisted candidate, not as a verified verbatim Codex response.

| Field | Your evidence |
|---|---|
| Original AI source (file, chat export, timestamp, or screenshot reference) | `adm_step5_sensitivity_report.md`, **Revenue-growth mechanics**, lines 78-88; matching narrative source: `adm_step5_sensitivity.py`, `build_report()`, lines 230-259. AI-assisted explanation; not a verified verbatim Codex response. |
| Exact suggestion/model decision | Increasing revenue growth can decrease free cash flow and DCF valuation when additional working-capital investment exceeds the increase in NOPAT, even though operating income increases. |
| Your action: accepted, corrected, qualified, or rejected | Confirmed classification: **QUALIFY**. |
| Reason/evidence for your action | From 2% to 4% growth, 2030 NOPAT increased $175.05m while operating working-capital investment increased $221.06m. FCFF decreased $46.01m and DCF value/share declined about $2.55. |
| Effect on model or recommendation | No changes to financial calculations. The explanation is valid for the model assumptions but does not prove ADM will experience these results. The recommendation remains watch/defer. |

The personal decision record is retained below together with the underlying evidence.

## Step 5 Revenue-Growth AI-Output Decision

### Documented candidate source

The candidate explanation appears under **“Revenue-growth mechanics”** in `adm_step5_sensitivity_report.md` (the generated report, lines 78–88). Its matching narrative source is `build_report()` in `adm_step5_sensitivity.py` (lines 230–259). The report’s AI-use disclosure (lines 145–147; matching source lines 316–318) says that Codex assisted with structuring the reproducible Step 5 script and report and running model checks.

The documented candidate statement says, in substance: holding gross margin, SG&A/gross profit, CapEx, days, and other ratios constant, higher revenue scales receivables, inventory, and other current assets; the resulting operating-NWC build can exceed incremental NOPAT, causing FCFF and DCF value/share to fall despite higher EBIT and NOPAT. It further states that the facility draws are financing cash flow, excluded from FCFF/current-date DCF bridge, and both endpoints remain within the $6,000m facility limit.

This is a genuine documented Step 5 explanation with a disclosed Codex-assistance record. The repository does not independently prove that every sentence was solely AI-authored, so this file identifies it as the candidate AI-output decision rather than attributing a personal decision to the student.

### Linked-model calculation evidence

The evidence was independently reproduced with the existing linked model by running `run_workbench({'revenue_growth': 0.02})` and `run_workbench({'revenue_growth': 0.04})`. The adapter in `adm_valuation_model.py` changes the scalar revenue-growth driver uniformly across 2026–2030 and uses `adm_integrated_model.run_model()` and `dcf()` rather than a separate valuation engine. In `adm_integrated_model.py`, revenue is forecast from prior-year revenue; receivables, inventory, other current assets, trade payables, and accrued payables determine operating NWC; FCFF is calculated as `EBIT × (1 − tax rate) + depreciation − CapEx − change in operating NWC`; and the DCF terminal value uses final-year FCFF.

Amounts are USD millions except per-share value. “Operating working-capital investment” is `− Change in operating NWC`, the cash-use presentation used in the Step 5 report.

| 2030 linked-model measure | 2.00% growth | 4.00% growth | 4% minus 2% |
|---|---:|---:|---:|
| EBIT | $838.871703m | $1,052.348381m | +$213.476677m |
| NOPAT (EBIT × 82%) | $687.874797m | $862.925672m | +$175.050875m |
| Operating working-capital investment | $190.317766m | $411.378884m | +$221.061119m |
| FCFF | $352.414617m | $306.404374m | −$46.010243m |
| DCF value/share | −$0.740876 | −$3.288931 | −$2.548055 |

Additional linked checks: the 2% and 4% cases both pass the $6,000m facility constraint. Their 2030 facility balances are $5,144.234317m and $5,670.061536m, respectively; the latter retains $329.938464m headroom. All non-facility accounting validations pass for both cases.

### Evidence assessment

| Portion of candidate explanation | Evidence assessment |
|---|---|
| Higher growth raises revenue, EBIT, and NOPAT while the specified operating ratios remain constant | Supported by the two linked-model runs and the one-driver adapter. |
| Incremental operating-NWC investment exceeds incremental NOPAT in 2030 | Supported: $221.061119m NWC increase exceeds the $175.050875m NOPAT increase by $46.010243m. |
| FCFF falls despite higher EBIT/NOPAT because depreciation and CapEx are unchanged and NWC investment rises | Supported by the FCFF formula and observed $46.010243m decline. |
| Lower FCFF leads to lower DCF value/share | Supported by the linked DCF result and the model’s terminal-value formula using final-year FCFF. |
| Both growth endpoints remain within the facility limit | Supported, but should be qualified: the 4% case has only $329.938464m 2030 headroom. |
| “Not a data error” / implication for a real-world revenue forecast | Incomplete unless qualified. The result verifies the model’s mechanical response, not whether 4% growth, fixed margins, fixed CapEx, or the working-capital ratios are empirically appropriate for ADM. |

### Final AI-Output Decision

**Confirmed classification: QUALIFY.** I agree with the explanation because the model shows that higher revenue growth increased operating income but also required more investment in working capital. The additional working-capital investment was greater than the increase in NOPAT, causing FCFF to decrease. However, these results are based on assumptions in the model and do not necessarily reflect what will happen to ADM. The explanation is therefore accepted as a model-mechanics explanation and qualified as a one-driver sensitivity, not as independent evidence about ADM’s likely future growth, working-capital needs, or recommendation.

| Personal decision record | Your entry |
|---|---|
| My final action: accepted, corrected, qualified, or rejected | **QUALIFY.** |
| Why I took that action | I agree with the explanation because the model shows that higher revenue growth increased operating income but also required more investment in working capital. The additional working-capital investment was greater than the increase in NOPAT, causing FCFF to decrease. However, these results are based on assumptions in the model and do not necessarily reflect what will happen to ADM. |
| Any wording I changed in the Step 5 explanation | I did not change the Step 5 wording; I documented this qualification in my Step 6 validation record. |
| Effect on my recommendation or further research | My recommendation remains watch/defer because the higher-growth scenario still produces a DCF valuation below the observed market price. I would want more evidence about ADM's working-capital requirements before changing my recommendation. |
